| Literature DB >> 33066100 |
Giovanni Battista Biserni1, Arianna Dondi1, Riccardo Masetti2, Jessica Bandini2, Ada Dormi3, Francesca Conti2, Andrea Pession2, Marcello Lanari1.
Abstract
During acute upper respiratory tract infections (AURTIs) caused by Adenoviruses, the mix of severe clinical presentation, together with elevation of white blood cells (WBCs) and C-reactive protein (CRP), often mimicking bacterial infection, leads to an inappropriate use of antibiotics. We studied 23 immunocompetent children admitted to our Pediatric Emergency Unit with signs of acute Adenoviral AURTIs, aiming at better clarifying the biological background sustaining this clinical presentation. Infection etiology was tested with nasopharyngeal swabs, serology, and DNA-PCR. During fever peaks and subsequent recovery, we assessed WBC count with differential, CRP, procalcitonin, serum concentration of six inflammatory cytokines, and lymphocyte subset populations.Entities:
Keywords: Adenovirus; acute upper respiratory tract infections; children; cytokine; immune system; lymphocytes populations subsets
Year: 2020 PMID: 33066100 PMCID: PMC7711544 DOI: 10.3390/vaccines8040602
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Common associations between general infection sites and Adenovirus (HAdV) species. Other HAdV species may also occur at the site of infection. Many HAdV species show great variability in their tissue tropism.
| Most Common Infection Sites | HAdV Species |
|---|---|
| Gastroenteritis | F and G |
| Pneumonia | B, C, and E |
| Hepatitis | C |
| Meningoencephalitis | A, B, and D |
| Cystitis | B |
| Keratoconjunctivitis | B and D |
Demographic and clinical characteristics of the population.
| Characteristic | Adenoviral AURTI |
|---|---|
| Gender, Male/Female | 15/8 |
| Age, mean (SD) | 2.2 years (1.594) |
| Days of fever, mean (SD) | 6.2 days (2.73) |
| Days of hospitalization, mean (SD) | 3.3 days (1.3) |
| Physical findings (number of patients) | Nasal discharge (22); |
| Pharyngitis (2019); | |
| Tonsillitis (15); | |
| Otitis (2); | |
| Bronchitis/Pneumonia (3); | |
| Conjunctivitis (1) | |
| Method for diagnosis (number of patients) | Adenoviral Antigen (14); |
| DNA PCR (110); | |
| Serology (6) | |
| Coinfections | None |
White blood cell (WBC) count, C-reactive protein (CRP), and Procalcitonin levels in 23 patients affected by Adenoviral AURTIs during the febrile (acute) and afebrile (convalescence) phases, p values reflect difference in means.
| Test | Acute Phase | CI or IR | Convalescence | CI or IR |
|
|---|---|---|---|---|---|
| WBC (/µL) | 12,880 | 10,870–16,990 * | 8144 | 6854–9435 | 0.002 |
| Neutrophils (/µL) | 7464 | 5522–9406 | 1870 | 1430–3170 * | 0.006 |
| (%) | 55.6% | 49.9–61.4% | 29.6% | 24.9–34.4% | 0.00 |
| Lymphocytes (/µL) | 5159 | 3916–6402 | 4898 | 4053–5743 | 0.66 |
| (%) | 34.6% | 28.9–40.2% | 60.1% | 54.8–66.4% | 0.00 |
| Monocytes (/µL) | 1241 | 941–1369 * | 554 | 373–735 | 0.005 |
| (%) | 9.5% | 8.1–10.8% | 6.4% | 4.9–7.9% | 0.008 |
| Eosinophils (/µL) | 30 | 10–120 * | 210 | 55–485 * | 0.003 |
| (%) | 0.2 | 0–1.3% * | 2.9 | 3.3–5.6% * | 0.001 |
| Basophils (/µL) | 20 | 10–40 * | 27 | 17–37 | 0.86 |
| (%) | 0.2 | 0.1–0.3% * | 0.3% | 0.2–0.4% | 0.035 |
| CRP (mg/dL) | 8.3 | 5.9–10.6 | 2.9 | 2–3.8 | 0.000 |
| Procalcitonin (ng/mL) | 1.2 | 0.3–3.15 * | 0.7 | 0.4–1 | 0.016 |
* Data not normally distributed.
Lymphocytes population expressed in concentration and percentage of total lymphocytes in 23 patients affected by Adenoviral AURTIs during the febrile (acute) and afebrile (convalescence) phases, p values reflect difference in means.
| Test | Acute Phase | CI or IR | Convalescence | CI or IR |
|
|---|---|---|---|---|---|
| Total lymphocytes (/µL) | 5159 | 3916–6402 | 4898 | 4053–5743 | 0.66 |
| (%) | 34.6% | 28.9–40.2% | 60.1% | 54.8–66.4% | 0.00 |
| Natural killer (/µL) | 414 | 235–562 * | 385 | 234–536 | 0.6782 |
| (%) | 9.9% | 7.3–12.5% | 6.6% | 4.2–9% | 0.3281 |
| B lymphocytes (/µL) | 782 | 439–1125 | 754 | 555–953 | 0.011 |
| (%) | 25.1% | 19.3–31.8% | 15.3% | 11.6–19% | 0.021 |
| T lymphocytes (/µL) | 2455 | 1482–3939 * | 2788 | 2099–3478 | 0.07 |
| (%) | 57.4% | 43.2–71.6% | 58.3% | 44.7–60% * | 0.77 |
| T Helper (T CD4+) (/µL) | 1159 | 675–1643 | 1831 | 1282–2381 | 0.071 |
| (%) | 40.15% | 31.7–48.6% | 33.4% | 25.1–42% | 0.391 |
| T CD4+ naïve (/µL) | 1513 | 1037–1989 | 845 | 450–1259 | 0.181 |
| (%) | 29.4% | 23.4–35.1% | 29% | 23.8–34.2% | 0.911 |
| T CD4+ memory (/µL) | 313 | 231–416 * | 272 | 232–457 * | 0.962 |
| (%) | 6.3% | 5.1–0.3% | 7.2% | 5.6–8.4% | 0.62 |
| T Cytotoxic (T CD8+) (/µL) | 594 | 433–1054 | 1241 | 638–1.844 | 0.572 |
| (%) | 14.8% | 9–26.5% | 16.3% | 13.2–19.4% | 0.682 |
| T CD8+ naïve (/µL) | 476 | 343–811 | 560 | 369–751 | 0.652 |
| (%) | 14.3% | 8.8–19.7% | 12.3% | 9.7–13.2% * | 0.772 |
| T CD8+ memory (/µL) | 78 | 48–132 * | 148 | 86–211 | 0.662 |
| (%) | 2.6% | 1.3–4% | 3.2% | 2–4.5% | 0.651 |
| T regulatory (/µL) | 2152 | 1763–2540 | 2471 | 2258–3120 * | 0.042 |
| (%) | 65.8% | 36.1–75.6% * | 61.8% | 25.1–79.2% * | 0.515 |
* data not normally distributed.
Inflammatory cytokines during the febrile (acute phase) and afebrile (convalescence) phases.
| Cytokine | Acute Phase | CI or IR | Convalescence | CI or IR |
|
|---|---|---|---|---|---|
| IL-6 (pg/mL) | 385.69 | 13.8–50.1 * | 18 | 4–17 * | 0.05 |
| IL-8 (pg/mL) | 1646.38 | 33–142 * | 458 | 19–144 * | 0.95 |
| IL12p70 (pg/mL) | 1.08 | 0–2 * | 1 | 0–0 * | 0.4 |
| IL-1β (pg/mL) | 7.00 | 0–3 * | 0 | 0–1 * | 0.26 |
| IL-10 (pg/mL) | 3.92 | 2.5–5 * | 2 | 1.2–2.7 | 0.007 |
| TNF α (pg/mL) | 9.62 | 1.5–19 * | 18 | 0–15 * | 0.6 |
* data not normally distributed.
Figure 1Inflammatory cytokines during the febrile (orange column) and afebrile (yellow column) phases. In ordinates, serum concentration of inflammatory cytokines in pg/mL. Asterisks represent significance at a p = 0.05 for IL-6 and p = 0.007 for IL-10, according to Wilcoxon sign-rank test.